Changes for page AstraZeneca
Last modified by Wilton Risenhoover on 2022/07/06 01:12
Change comment:
There is no comment for this version
Summary
-
Page properties (2 modified, 0 added, 0 removed)
-
Objects (0 modified, 1 added, 0 removed)
Details
- Page properties
-
- Tags
-
... ... @@ -1,1 +1,1 @@ 1 -US:AZN 1 +US:AZN|GB:AZN - Content
-
... ... @@ -6,13 +6,11 @@ 6 6 7 7 * AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. 8 8 * The company focus on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. 9 -* The company also has an active R&D presence in 40 other countries spanning the globe with 0,000 - employees work exclusively in R&D. 9 +* The company also has an active R&D presence in 40 other countries spanning the globe with 10,000 - employees work exclusively in R&D. 10 10 * Commercial teams of around 43,400 employees are active in more than 100 countries 11 11 12 - 13 13 [[image:AZN0.png||height="175" width="721"]] 14 14 15 - 16 16 = Company Overview = 17 17 18 18 AstraZeneca (LSE:AZN, NASDAQ:AZN) is a global, science-led biopharmaceutical business and its innovative medicines are used by millions of patients worldwide.{{footnote}}https://www.astrazeneca.com/our-company.html{{/footnote}} ... ... @@ -32,7 +32,6 @@ 32 32 * 40 - active R&D presence in other countries spanning the globe 33 33 * 10,000 - employees work exclusively in R&D 34 34 35 - 36 36 The company's pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. 37 37 38 38 * 175projects in its pipeline ... ... @@ -39,7 +39,6 @@ 39 39 * 17new molecular entities in its late-stage pipeline 40 40 * 1new molecular entity approval 41 41 42 - 43 43 [[image:AZN4.png||alt="AZN2.png"]] 44 44 45 45 ... ... @@ -86,7 +86,6 @@ 86 86 * Building expertise and leadership in the most prevalent and highest mortality rate tumour types 87 87 * Delivering across its global footprint 88 88 89 - 90 90 **key disease areas** 91 91 92 92 The company's focus is on some of the most hostile and hard-to-treat cancers. By understanding the complexities of cancer, the company hope to achieve life-changing benefits for patients. ... ... @@ -265,7 +265,6 @@ 265 265 * Alexion integration progressing well, creating new opportunities in rare diseases 266 266 * Operating Expenses in the quarter reflected the addition of Alexion, as well increased R&D expenses across multiple programs, investment in its COVID-19 medicines, and increased SG&A from pre-launch activities following successful pipeline delivery 267 267 268 - 269 269 **Pascal Soriot, Chief Executive Officer, commented:** 270 270 271 271 AstraZeneca’s scientific leadership continues to provide strong revenue growth and exceptional pipeline delivery, with eight positive late-stage readouts across seven medicines since June, including its long acting antibody combination showing promise in both prevention and treatment of COVID-19. The addition of Alexion furthers its commitment to bring transformative therapies to patients around the world, and I am proud of its colleagues’ ongoing dedication and focus. ... ... @@ -284,7 +284,6 @@ 284 284 * In the US, Total Revenue increased by 29% to $8,305m and in Europe by 40% (31% at CER) to $5,178m, including pandemic COVID-19 vaccine revenue of $736m 285 285 * Growth in Core EPS13 to $5.05 to $5.40, in line with prior guidance. 286 286 287 - 288 288 Oncology Total Revenue of $9,744m in the year to date; an increase of 19% (16% at CER). Oncology represented 38% of overall Total Revenue (YTD 2020: 43%). 289 289 290 290
- XWiki.XWikiComments[0]
-
- Author
-
... ... @@ -1,0 +1,1 @@ 1 +XWiki.AsifF - Comment
-
... ... @@ -1,0 +1,2 @@ 1 +Recent investor presentation 2 +https://www.astrazeneca.com/content/dam/az/PDF/2021/q3/Year-to-date_and_Q3_2021_results_presentation.pdf - Date
-
... ... @@ -1,0 +1,1 @@ 1 +2022-01-12 13:31:12.795